SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	*Isocitrate dehydrogenase 1* (*IDH1*)	*In vitro* studies suggest inhibiting oxidative metabolism could help treat *IDH1*-mutant cancers. In human colon cancer cell lines, heterozygous expression of a loss-of-function *IDH1* mutant resulted in greater metabolic impairment under hypoxic conditions than expression of either wild-type *IDH1* or an *IDH2* mutant. In cultured *IDH1* mutant–expressing cells, pharmacological inhibition of oxidative metabolism resulted in more potent growth inhibition than that seen in parental cells. Next steps could include testing therapeutic candidates that block oxidative metabolism in animal cancer models. Agios Pharmaceuticals Inc. has the IDH1 inhibitor AG-120 in Phase I testing to treat cancer. *SciBX* 7(21); doi:10.1038/scibx.2014.607 **Published online May 29, 2014**	Patent and licensing status unavailable	Grassian, A.R. *et al. Cancer Res.*; published online April 22, 2014; doi:10.1158/0008-5472.CAN-14-0772-T **Contact:** Christian M. Metallo, University of California, San Diego, La Jolla, Calif. e-mail: cmetallo@ucsd.edu